Physician profile
Lee Congleton
NPI 1699775718
$3,358.23
in general payments reported to CMS, 2019-2025
27 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $740 · 2020: $47.09 · 2021: $179 · 2022: $555 · 2023: $309 · 2024: $878 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $811.56 | 2019-2025 | Rezum Generator, Spaceoar Vue System - 10ml, General - Erectile Dysfunction |
| C. R. Bard, INC. & Subsidiaries | $553.43 | 2023-2025 | Bard Urinary Drainage Bag, Purewick Female External Catheter, Magic3 Go Intermittent Urinary Catheter |
| Rochester Medical Corporation | $345.61 | 2022 | |
| Amgen INC. | $236.48 | 2019-2020 | |
| Abbvie INC. | $185.48 | 2022-2025 | Botox |
| Allergan, INC. | $156.48 | 2019-2021 | |
| Axonics, INC. | $135.93 | 2021-2024 | Bulkamid, Axonics |
| Astellas Pharma US INC | $99.19 | 2019 | |
| Intuitive Surgical, INC. | $98.90 | 2024 | |
| Myovant Sciences INC. | $92.19 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $89.48 | 2019-2025 | Adstiladrin |
| Sumitomo Pharma America, INC. | $81.73 | 2023-2024 | Orgovyx |
| Procept Biorobotics Corporation | $80.33 | 2024 | Aquabeam System |
| Teleflex LLC | $62.44 | 2021-2025 | Urolift |
| Valencia Technologies Corporation | $56.64 | 2025 | Ecoin Device Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $40.84 | 2019-2025 | Erleada |
| Neotract INC. | $32.69 | 2019 | |
| Pfizer INC. | $30.05 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $29.56 | 2019 | |
| Ambu INC. | $23.14 | 2020 | |
| Progenics Pharmaceuticals, INC. | $22.64 | 2025 | |
| 180 Medical, INC. | $17.89 | 2022 | |
| Laborie Medical Technologies Corp. | $17.78 | 2025 | |
| Urogen Pharma, INC. | $17.02 | 2024 | |
| Urovant Sciences INC | $15.16 | 2022 | |
| Olympus America INC. | $13.77 | 2019 | |
| Medtronic USA, INC. | $11.82 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Congleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.